<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30205418</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2005-1212</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Gut and liver</Title>
          <ISOAbbreviation>Gut Liver</ISOAbbreviation>
        </Journal>
        <ArticleTitle>IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.</ArticleTitle>
        <Pagination>
          <StartPage>300</StartPage>
          <EndPage>307</EndPage>
          <MedlinePgn>300-307</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.5009/gnl18085</ELocationID>
        <Abstract>
          <AbstractText>Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis and currently includes three categories: primary sclerosing cholangitis (PSC), secondary cholangitis, and IgG4-related sclerosing cholangitis (IgG4-SC). SC categories share similar clinical features, such as cholestasis. Patients with SC present with cholestatic symptoms, including jaundice and pruritus, and blood tests reveal elevation of cholestatic enzymes. Cholangiography, endoscopic or magnetic, is inevitably required for making a diagnosis. Although the presentation of IgG4-SC and PSC are similar, the comorbidities, treatment response, and outcomes differ significantly, and therefore, it is strongly advisable to be familiar with these two diseases to make a correct diagnosis. Differentiation of cholangiocarcinoma from IgG4-SC and PSC is also extremely important. In this review, the clinical characteristics, comorbidities, treatment and outcomes of IgG4-SC and PSC will be outlined based on experience mainly from Japan.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tanaka</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Gut Liver</MedlineTA>
        <NlmUniqueID>101316452</NlmUniqueID>
        <ISSNLinking>1976-2283</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015209" MajorTopicYN="N">Cholangitis, Sclerosing</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002779" MajorTopicYN="N">Cholestasis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077733" MajorTopicYN="N">Immunoglobulin G4-Related Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cholangiography</Keyword>
        <Keyword MajorTopicYN="Y">Cholangitis</Keyword>
        <Keyword MajorTopicYN="Y">Corticosteroid</Keyword>
        <Keyword MajorTopicYN="Y">IgG4</Keyword>
      </KeywordList>
      <CoiStatement><b>CONFLICTS OF INTEREST</b>. No potential conflict of interest relevant to this article was reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30205418</ArticleId>
        <ArticleId IdType="pmc">PMC6529173</ArticleId>
        <ArticleId IdType="doi">10.5009/gnl18085</ArticleId>
        <ArticleId IdType="pii">gnl18085</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–1170. doi: 10.1056/NEJMra1506330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1506330</ArticleId>
            <ArticleId IdType="pmc">PMC5553912</ArticleId>
            <ArticleId IdType="pubmed">27653566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis: a comprehensive review. J Hepatol. 2017;67:1298–1323. doi: 10.1016/j.jhep.2017.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.07.022</ArticleId>
            <ArticleId IdType="pubmed">28802875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakazawa T, Naitoh I, Hayashi K, Miyabe K, Simizu S, Joh T. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol. 2013;19:7661–7670. doi: 10.3748/wjg.v19.i43.7661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v19.i43.7661</ArticleId>
            <ArticleId IdType="pmc">PMC3837265</ArticleId>
            <ArticleId IdType="pubmed">24282356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka A, Tazuma S, Nakazawa T, et al.  No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci. 2017;24:217–225. doi: 10.1002/jhbp.432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jhbp.432</ArticleId>
            <ArticleId IdType="pubmed">28103424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka A, Tazuma S, Okazaki K, et al.  Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017;15:920–926.e3. doi: 10.1016/j.cgh.2016.12.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2016.12.038</ArticleId>
            <ArticleId IdType="pubmed">28111336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, et al.  IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol. 2015;48:198–206. doi: 10.1007/s12016-014-8430-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-014-8430-2</ArticleId>
            <ArticleId IdType="pubmed">24958363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deshpande V, Zen Y, Chan JK, et al.  Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–1192. doi: 10.1038/modpathol.2012.72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2012.72</ArticleId>
            <ArticleId IdType="pubmed">22596100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khosroshahi A, Wallace ZS, Crowe JL, et al.  International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67:1688–1699. doi: 10.1002/art.39132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39132</ArticleId>
            <ArticleId IdType="pubmed">25809420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone JH, Khosroshahi A, Deshpande V, et al.  Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–3067. doi: 10.1002/art.34593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34593</ArticleId>
            <ArticleId IdType="pmc">PMC5963880</ArticleId>
            <ArticleId IdType="pubmed">22736240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umehara H, Okazaki K, Masaki Y, et al.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22:1–14. doi: 10.3109/s10165-011-0508-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0508-6</ArticleId>
            <ArticleId IdType="pmc">PMC3278618</ArticleId>
            <ArticleId IdType="pubmed">21881964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umehara H, Okazaki K, Masaki Y, et al.  Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30. doi: 10.3109/s10165-011-0571-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0571-z</ArticleId>
            <ArticleId IdType="pubmed">22218969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki K, Uchida K, Ikeura T, Takaoka M. Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system. J Gastroenterol. 2013;48:303–314. doi: 10.1007/s00535-012-0744-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-012-0744-3</ArticleId>
            <ArticleId IdType="pmc">PMC3698437</ArticleId>
            <ArticleId IdType="pubmed">23417598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamano H, Kawa S, Horiuchi A, et al.  High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–738. doi: 10.1056/NEJM200103083441005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM200103083441005</ArticleId>
            <ArticleId IdType="pubmed">11236777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamisawa T, Funata N, Hayashi Y, et al.  A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38:982–984. doi: 10.1007/s00535-003-1175-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-003-1175-y</ArticleId>
            <ArticleId IdType="pubmed">14614606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohara H, Okazaki K, Tsubouchi H, et al.  Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–542. doi: 10.1007/s00534-012-0521-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00534-012-0521-y</ArticleId>
            <ArticleId IdType="pubmed">22717980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beuers U, Hubers LM, Doorenspleet M, et al.  IgG4-associated cholangitis: a mimic of PSC. Dig Dis. 2015;33(Suppl 2):176–180. doi: 10.1159/000440830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000440830</ArticleId>
            <ArticleId IdType="pubmed">26641633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doorenspleet ME, Hubers LM, Culver EL, et al.  Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology. 2016;64:501–507. doi: 10.1002/hep.28568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.28568</ArticleId>
            <ArticleId IdType="pmc">PMC5017301</ArticleId>
            <ArticleId IdType="pubmed">27015613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghazale A, Chari ST, Zhang L, et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–715. doi: 10.1053/j.gastro.2007.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2007.12.009</ArticleId>
            <ArticleId IdType="pubmed">18222442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chari ST, Smyrk TC, Levy MJ, et al.  Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010–1016. doi: 10.1016/j.cgh.2006.05.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2006.05.017</ArticleId>
            <ArticleId IdType="pubmed">16843735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanno A, Masamune A, Okazaki K, et al.  Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas. 2015;44:535–539. doi: 10.1097/MPA.0000000000000325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPA.0000000000000325</ArticleId>
            <ArticleId IdType="pubmed">25815647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huggett MT, Culver EL, Kumar M, et al.  Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109:1675–1683. doi: 10.1038/ajg.2014.223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2014.223</ArticleId>
            <ArticleId IdType="pmc">PMC4552254</ArticleId>
            <ArticleId IdType="pubmed">25155229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Buy Wenniger LJ, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology. 2014;60:1453–1454. doi: 10.1002/hep.26999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26999</ArticleId>
            <ArticleId IdType="pmc">PMC4258085</ArticleId>
            <ArticleId IdType="pubmed">24407836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakazawa T, Naitoh I, Hayashi K, et al.  Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol. 2012;47:79–87. doi: 10.1007/s00535-011-0465-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-011-0465-z</ArticleId>
            <ArticleId IdType="pubmed">21947649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2010;24:655–666. doi: 10.1016/j.bpg.2010.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpg.2010.07.005</ArticleId>
            <ArticleId IdType="pubmed">20955968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382:1587–1599. doi: 10.1016/S0140-6736(13)60096-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)60096-3</ArticleId>
            <ArticleId IdType="pubmed">23810223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giljaca V, Poropat G, Stimac D, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2010;(1):CD004036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7163281</ArticleId>
            <ArticleId IdType="pubmed">20091555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parkes M, Booth JC, Pillai G, Mee AS. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol. 2001;33:319–322. doi: 10.1097/00004836-200110000-00013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004836-200110000-00013</ArticleId>
            <ArticleId IdType="pubmed">11588548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48(Suppl 1):S38–S57. doi: 10.1016/j.jhep.2008.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2008.01.020</ArticleId>
            <ArticleId IdType="pubmed">18304683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol. 2005;28:93–103. doi: 10.1385/CRIAI:28:2:093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1385/CRIAI:28:2:093</ArticleId>
            <ArticleId IdType="pubmed">15879616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103. doi: 10.1080/00365529850166284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/00365529850166284</ArticleId>
            <ArticleId IdType="pubmed">9489916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17:908–913. doi: 10.1046/j.1440-1746.2002.02835.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1440-1746.2002.02835.x</ArticleId>
            <ArticleId IdType="pubmed">12164967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambha K, Kim WR, Talwalkar J, et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–1369. doi: 10.1016/j.gastro.2003.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gastro.2003.07.011</ArticleId>
            <ArticleId IdType="pubmed">14598252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:1929–1930. doi: 10.1053/j.gastro.2004.04.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2004.04.052</ArticleId>
            <ArticleId IdType="pubmed">15188211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–1049. doi: 10.1111/j.1572-0241.2007.01103.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2007.01103.x</ArticleId>
            <ArticleId IdType="pubmed">17313496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939–944. doi: 10.1016/j.jhep.2008.02.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2008.02.017</ArticleId>
            <ArticleId IdType="pubmed">18433916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–577. doi: 10.1002/hep.23678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.23678</ArticleId>
            <ArticleId IdType="pubmed">20683956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:83. doi: 10.1186/1471-230X-11-83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-230X-11-83</ArticleId>
            <ArticleId IdType="pmc">PMC3160402</ArticleId>
            <ArticleId IdType="pubmed">21767410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H, Manne S, Shick J, Lissoos T, Dolin P. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine (Baltimore) 2017;96:e7116. doi: 10.1097/MD.0000000000007116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000007116</ArticleId>
            <ArticleId IdType="pmc">PMC5478316</ArticleId>
            <ArticleId IdType="pubmed">28614231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188. doi: 10.1016/j.jhep.2011.10.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2011.10.025</ArticleId>
            <ArticleId IdType="pubmed">22245904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aabakken L, Karlsen TH, Albert J, et al.  Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline. Endoscopy. 2017;49:588–608. doi: 10.1055/s-0043-107029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0043-107029</ArticleId>
            <ArticleId IdType="pubmed">28420030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver. 2018;12:17–29. doi: 10.5009/gnl16510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5009/gnl16510</ArticleId>
            <ArticleId IdType="pmc">PMC5753680</ArticleId>
            <ArticleId IdType="pubmed">28376583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Njei B, McCarty TR, Varadarajulu S, Navaneethan U. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2016;44:1139–1151. doi: 10.1111/apt.13817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.13817</ArticleId>
            <ArticleId IdType="pubmed">27696456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Kowdley KV, Luketic VA, et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808–814. doi: 10.1002/hep.23082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.23082</ArticleId>
            <ArticleId IdType="pmc">PMC2758780</ArticleId>
            <ArticleId IdType="pubmed">19585548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman R, Fevery J, Kalloo A, et al.  Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678. doi: 10.1002/hep.23294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.23294</ArticleId>
            <ArticleId IdType="pubmed">20101749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindor KD, Kowdley KV, Harrison ME American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–659. doi: 10.1038/ajg.2015.112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2015.112</ArticleId>
            <ArticleId IdType="pubmed">25869391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11:841–846. doi: 10.1016/j.cgh.2012.12.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2012.12.032</ArticleId>
            <ArticleId IdType="pubmed">23353641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to &lt;1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58:329–334. doi: 10.1016/j.jhep.2012.10.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.10.013</ArticleId>
            <ArticleId IdType="pubmed">23085647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rupp C, Rössler A, Halibasic E, et al.  Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014;40:1292–1301. doi: 10.1111/apt.12979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apt.12979</ArticleId>
            <ArticleId IdType="pubmed">25316001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43:309–313. doi: 10.1016/j.dld.2010.12.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dld.2010.12.008</ArticleId>
            <ArticleId IdType="pmc">PMC3057302</ArticleId>
            <ArticleId IdType="pubmed">21251891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032–1039. doi: 10.1097/MCG.0b013e3181646713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCG.0b013e3181646713</ArticleId>
            <ArticleId IdType="pubmed">18580600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotthardt DN, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc. 2010;71:527–534. doi: 10.1016/j.gie.2009.10.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gie.2009.10.041</ArticleId>
            <ArticleId IdType="pubmed">20189511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egawa H, Ueda Y, Ichida T, et al.  Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant. 2011;11:518–527. doi: 10.1111/j.1600-6143.2010.03402.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-6143.2010.03402.x</ArticleId>
            <ArticleId IdType="pubmed">21219581</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
